Navigation Links
Vion Pharmaceuticals Announces FDA Lift of Clinical Hold on Phase III Study of Cloretazine(R) (VNP40101M) and Cytarabine in Relapsed AML
Date:1/8/2008

erly patients with de novo poor-risk AML. Preliminary data from this study were presented at the 2007 Annual Meeting of the American Society of Hematology (ASH(R)) in December 2007.

Conference Call Details

Vion will hold a conference call on Tuesday, January 8, 2008, at 10:30 a.m. Eastern Time. To participate in the conference call, please dial (866) 825-3209 in the U.S. (617) 213-8061 for international callers) at least 15 minutes before the start of the call. When prompted for a passcode, please enter 77697895. An audio webcast of the call will be accessible at http://www.vionpharm.com. Those who wish to listen to the conference call on the Web should visit the Investor Relations section of the Company's website at least 15 minutes prior to the event broadcast, and follow the instructions provided to assure that the necessary audio applications are downloaded and installed. These programs can be obtained at no charge to the user. A replay of the call will be available two hours after the completion of the call at (888) 286-8010 in the U.S. ((617) 801-6888 for international callers), pass code 45545274.

Vion Pharmaceuticals, Inc. is committed to extending the lives and improving the quality of life of cancer patients worldwide by developing and commercializing innovative cancer therapeutics. Vion has two agents in clinical trials. Cloretazine(R) (VNP40101M), a unique alkylating agent, is being evaluated in a Phase II pivotal trial as a single agent in elderly patients with previously untreated de novo poor-risk acute myelogenous leukemia. Clinical trials of Cloretazine(R) (VNP40101M) as a single agent in small cell lung cancer, with temozolomide in brain tumors, and with stem cell transplantation in advanced hematologic malignancies, are also being conducted. Triapine(R), a potent inhibitor of a key step in DNA synthesis, is being evaluated in clinical trials sponsored by the National Cancer
'/>"/>

SOURCE Vion Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
2. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
3. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
4. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
5. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
6. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
7. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
8. Nabi Biopharmaceuticals Announces Second Quarter 2007 Financial Results
9. Access Pharmaceuticals Provides Update on Clinical Development Plan of ProLindac
10. Quark Pharmaceuticals Extends Research Agreement with State University of New York for Proprietary siRNA Compounds for Acute Hearing Loss
11. Acura Pharmaceuticals, Inc. Secures Financing to Fund Pivotal Phase III Clinical Trial for Lead Aversion(R) Technology Product Candidate
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2015)... 2015 /PRNewswire/ - Anything Technologies Media, Inc. (OTC:EXMT) has ... Garden Solutions (FIGS), www.frontiergarden.com has been ... Project Manager for a My Compassion originated medical ... located in Alaska.  The project will be funded ... Teaming Partners. The first phase of the project, ...
(Date:7/30/2015)... 30, 2015  Arena Pharmaceuticals, Inc. (NASDAQ: ARNA ... and webcast at 5:00 p.m. Eastern Time (2:00 p.m. ... second quarter 2015 financial results and provide a corporate ... NASDAQ Global Select Market closes that day. ... for domestic callers and 914.495.8552 for international callers. Please ...
(Date:7/30/2015)...  Alimera Sciences, Inc. (NASDAQ: ALIM ) (Alimera), ... and commercialization of prescription ophthalmic pharmaceuticals, today announced that ... financial results after the market close on Monday, August ... the same day at 4:30 p.m. ET. ... Officer, and Rick Eiswirth , Chief Operating Officer ...
Breaking Medicine Technology:Frontier Indoor Garden Solutions announced as Horticultural Supplier and Project Manager for Alaskan Tribal Medical Marijuana Grow Facility 2Frontier Indoor Garden Solutions announced as Horticultural Supplier and Project Manager for Alaskan Tribal Medical Marijuana Grow Facility 3Arena Pharmaceuticals to Host Second Quarter 2015 Financial Results and Corporate Update Conference Call and Webcast on Wednesday, August 5 2Arena Pharmaceuticals to Host Second Quarter 2015 Financial Results and Corporate Update Conference Call and Webcast on Wednesday, August 5 3Arena Pharmaceuticals to Host Second Quarter 2015 Financial Results and Corporate Update Conference Call and Webcast on Wednesday, August 5 4Alimera Sciences To Release Second Quarter Fiscal Year 2015 Financial Results 2
(Date:7/30/2015)... FL (PRWEB) , ... July 30, 2015 , ... Using ... eradicate suicide and teach people more effective ways to prevent and manage major depression. ... to react fast enough, so people fall through the cracks and die needlessly everyday,” ...
(Date:7/30/2015)... ... July 30, 2015 , ... Between 2012 and 2014 ... Health News Florida on June 17th. Those untreated heroin use disorders share ... prevent the spread of dirty needles throughout the community. Ultimately Florida’s HIV infection rates ...
(Date:7/30/2015)... ... July 30, 2015 , ... ... (DEA) Acting Administrator Chuck Rosenberg’s announcement of the reinstitution of National Prescription Drug ... September 26, 2015 from 10:00 AM to 2:00 PM local time. On the ...
(Date:7/30/2015)... ... July 30, 2015 , ... InventHelp, a leading inventor service ... personal-care device that makes it easy to apply lotion or medication to a hard-to-reach ... assistance when applying lotion or medication to the back, and provides thorough coverage. The ...
(Date:7/30/2015)... , ... July 30, 2015 , ... ... at multinational organizations and NGO’s, according to a new survey by leading international ... that property damage and employee medical expenses represented the largest sources of financial ...
Breaking Medicine News(10 mins):Health News:Happiness Expert Develops Pioneering Online Tools for Sufferers of Major Depression, and Who may be Suicidal 2Health News:Happiness Expert Develops Pioneering Online Tools for Sufferers of Major Depression, and Who may be Suicidal 3Health News:HIV Rates Rise in S. Florida, Harbor Village Comments on Health News Florida's Recent Article 2Health News:HIV Rates Rise in S. Florida, Harbor Village Comments on Health News Florida's Recent Article 3Health News:AAPCC Supports National Prescription Drug Take-Back Day 2Health News:AAPCC Supports National Prescription Drug Take-Back Day 3Health News:InventHelp® Client Patents “My Back Buddy” – Device Could Apply Lotion to Hard-to-Reach Areas Easily 2Health News:New Clements Worldwide Global Risk Survey Shows Political Risk and Instability Top Managers' Concerns 2Health News:New Clements Worldwide Global Risk Survey Shows Political Risk and Instability Top Managers' Concerns 3
... Warwick have discovered high doses of thiamine vitamin B1 ... , Kidney disease, or diabetic nephropathy, develops progressively in patients ... assessed by a high excretion rate of the protein albumin ... The research is led by Dr Naila Rabbani and Professor ...
... one of seven centers to receive a four-year grant ... cutting edge genomic technologies to better understand lung disease. ... study to probe the causes of chronic obstructive pulmonary ... characterized by airflow limitation. , COPD is the ...
... Texas, Dec. 8 LifeCare Holdings, Inc., today,announced the ... marketing,for the 20-hospital long term acute care hospital system. ... , A proven ... management experience to LifeCare, including experience in senior,marketing, business ...
... should not determine whether an older patient with acute ... cell transplant from a matched donor, researchers of the ... today at the 50th annual meeting of the American ... just as well as younger patients with transplants that ...
... generic prescriptions from Jan 1 - June 30, 2009; BCBSNC,s 2008 "Medication ... total of $13 million on out-of-pocket costs; The 2009 generic copay waiver ... ... NC (Vocus) December 8, 2008 -- Blue Cross and Blue Shield ...
... Dec. 8 /PRNewswire/ - CHOC Children,s, a regional pediatric ... Orange, California facility on its newly commissioned RIVA (Robotic ... IV syringes and bags, is manufactured by Intelligent Hospital ... Vice President of Sales and Marketing for IH Systems, ...
Cached Medicine News:Health News:Vitamin B1 could reverse early-stage kidney disease in diabetes patients 2Health News:Boston University School of Medicine receives a grant to study chronic obstructive pulmonary disease 2Health News:Older age doesn't affect survival after bone marrow transplant 2Health News:BCBSNC Helps Customers Fight Recession With Free Generics 2Health News:BCBSNC Helps Customers Fight Recession With Free Generics 3Health News:BCBSNC Helps Customers Fight Recession With Free Generics 4Health News:CHOC Children's Draws First Patient Dose With RIVA System 2
... new Oculus Easygraph is a corneal ... tools you need for refractive surgery, ... therapy contact lens fitting in a ... 4" package. All you need to ...
The only ergonomic work station of its kind with an optional built-in keratograph and flat-screen. The Concepta is a modern workstation for the examination and refraction of patients....
The natural look of 3 in 1 technology in virtually any prescription....
Dot matrix pattern for light eyed patients....
Medicine Products: